
Basic Protective Measures Against COVID-19
COVID-19 is a new strain of the common cold that has been p...
COVID-19 is a new strain of the common cold that has been p...
Niraparib is indicated as a maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. This is usually used in patients who are in complete or partial response to platinum-based chemotherapy. This medication is usually started within 8 weeks following the most recent platinum-containing regimen.
The epithelial ovarian, fallopian tube or primary peritoneal cancers are diseases in which malignant cells form in the tissue covering the ovary or lining the fallopian tube. The epithelial ovarian, fallopian tube, or primary peritoneal cancers form in the same type of tissue and are treated the same way. Sometimes, these conditions are caused by inherited gene mutations. The genes in cells carry the hereditary information that is received from a person’s parents. The epithelial ovarian, fallopian tube or primary peritoneal cancers may not cause early signs or symptoms when signs and symptoms do appear, the cancer is often advanced. Signs and symptoms may include:
The ovaries are a pair of organs in the female reproductive system. They are in the pelvis. Each ovary is about the size and shape of an almond. The ovaries make eggs and female hormones.
The fallopian tubes are a pair of long slender tubes one on each side of the uterus. Cancer sometimes begins at the end of the fallopian tube near the ovary and spreads to the ovary.
The peritoneum is the tissue that lines the abdominal wall and covers organs in the abdomen. Primary peritoneal cancer forms in the peritoneum.
Niraparib is in the class of PARP inhibitors. This drug is a white to off-white and non-hygroscopic crystalline solid. This comes as a capsule that contains 159.4 Niraparib and is equivalent to 100 mg free bases as the active ingredient. The Food and Drug Administration (FDA) has already approved this prescription.
How does Niraparib work?
Niraparib is a poly ADP-ribose polymerase (PARP) enzyme inhibitor. It is highly selective for PARP1 and PARP2. PARP1 and PARP2 are involved in detecting DNA damage and promote repair. Inhibiting PARP1and PARP2 enzymatic activity results in DNA damage, apoptosis, and cell death. This medication induces cytotoxicity in tumor cell lines with or without BRCA1/2 deficiencies.
How to use Niraparib?
This medication is taken by mouth at bedtime to lessen the risk of nausea and vomiting. Each dose of this drug may be taken with or without food. Swallow the medicine as a whole with a full glass of water. Do not crush or dissolve the drug. Do not change your dose or stop taking this unless your doctor tells you to do so. If you missed a dose, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose.
The dosage is based on your medical condition and response to the treatment. Your doctor may start giving a lower dose with this medication and gradually increase it. If you vomit after taking Niraparib do not take another dose just continue your regular dosing schedule. Your doctor may reduce your dose or permanently or temporarily stop your treatment if you experience certain side effects. Be sure to tell your doctor about how you feel during your treatment with Niraparib.
What are the side effects of Niraparib?
Common side effects:
Seek a medical emergency right away if you have a fever of 38 C or higher with chills or any possible signs of infection. If you have any other side effects that won’t go away, let your doctor know at once.
Precautions